[CAS NO. 1802678-42-7] Vimirogant hydrochloride
PRODUCTS SPECIFICATIONS [1802678-42-7]
DESCRIPTION [1802678-42-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | C27H35F3N4O3S.xHCl |
| SMILES | O=C(C1=CN=C([C@H](C(C)C)N(C[C@H]2CC[C@H](C(F)(F)F)CC2)C3)C3=C1)NCC4=NC=C(S(=O)(CC)=O)C=C4.Cl.[x] |
Summary
Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor ( K i =3.5 nM; IC 50 =17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC 50 =57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research [1] [2] .
IC50 & Target
|
RORγt 3.5 nM (Ki) |
RORγt 17 nM (IC 50 ) |
In Vitro
Vimirogant hydrochloride inhibits the secretion of IL-17A from activated hPBMCs (IC 50 =18 nM) and human whole blood (IC 50 =192 nM) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
In the MOG35-55/CFA immunized mouse EAE model, Vimirogant hydrochloride (p.o.) significantly suppresses clinical symptoms, demyelination and mRNA expression of multiple inflammatory markers in the spinal cord [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02555709 | Vitae Pharmaceuticals Inc., an Allergan affiliate|Vitae Pharmaceuticals, Inc. |
Psoriasis
|
August 2015 | Phase 1|Phase 2 |
| NCT03724292 | Vitae Pharmaceuticals Inc., an Allergan affiliate|Vitae Pharmaceuticals, Inc. |
Psoriasis
|
August 1, 2015 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 125 mg/mL (Need ultrasonic)
Ethanol : 50 mg/mL (Need ultrasonic)
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 6.25 mg/mL (Infinity mM); Clear solution
-
3.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 6.25 mg/mL (Infinity mM); Clear solution
-
4.
-
5.
Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (Infinity mM); Clear solution
-
6.
Add each solvent one by one: 10% EtOH >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (Infinity mM); Clear solution
References
- [1] Gege C. RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345. Expert Opin Ther Pat. 2017;27(1):1-8.
- [2] Gerard McGeehan, et al. VTP-43742 is a potent and selective RORγt blocker that demonstrates oral efficacy in a mouse model of autoimmunity through suppression of IL-17A production (THER7P.945). J Immunol May 1, 2015, 194 (1 Supplement) 208.5-208.5.
